NCT06914713Recruiting
Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF
Efficacy Evaluation of Jin-shui Huan-xian Formula in Retarding the Decline of Pulmonary Function in IPF
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
This study is to evaluate the clinical efficacy and safety of Jin-shui Huan-xian Formula in retarding the decline of pulmonary function in IPF, generate high - quality clinical evidence, and establish a treatment plan of Jin-shui Huan-xian Formula for retarding the decline of pulmonary function in Idiopathic Pulmonary Fibrosis（IPF）
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 384 (estimated)
- First submitted
- 31 Mar 2025
- Start date
- 8 Sept 2025
- Primary completion date
- 30 Dec 2027
- Lead sponsor
- Henan University of Traditional Chinese Medicine
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT06914713
What you commit to
- Study type: Interventional
- Planned participants: 384
- From 8 Sept 2025 to the primary completion date, 30 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have participated in other clinical trials within 1 month before enrollment.
Other illness
- Patients complicated with other pulmonary diseases such as chronic obstructive pulmonary disease (COPD), lung cancer, active pulmonary tuberculosis, bronchiectasis, and pulmonary embolism.
- Patients with severe joint, peripheral nerve, and peripheral vascular diseases that affect limb movement and who are bed - ridden for a long time and cannot complete the six - minute walk test.
- Patients complicated with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, heart function grade 3 or above, stroke, cerebral hemorrhage, etc.).
- Patients with unclear consciousness, various mental illnesses, etc., who cannot communicate normally.
- Patients known to be allergic to any of the test medications and their components.
Lab values
- Patients complicated with liver diseases such as cirrhosis or secondary portal hypertension, bleeding caused by esophageal and gastric varices, patients with kidney diseases requiring dialysis or kidney transplantation, or patients with abnormal liver and kidney functions (ALT, AST, and BUN are 1.5 times higher than the upper limit of the normal range, and blood Cr is higher than the upper limit of the normal range).
Other
- Patients in the acute exacerbation phase of IPF.
- Pregnant or lactating women and patients with a recent plan for pregnancy.
Who the study is looking for
- Patients who meet the diagnostic criteria for IPF.
- Pulmonary function: The percentage of forced vital capacity (FVC) to the predicted value is ≥ 50%; and the percentage of the diffusing capacity of the lung for carbon monoxide (DLCO) to the predicted value is ≥ 30%.
- Patients who meet the syndrome - differentiation criteria for lung - qi deficiency syndrome, lung - and - kidney qi deficiency syndrome, etc.
- Aged between 40 and 85 years old.
- Patients who voluntarily accept the treatment and sign the informed consent
Age in the registry: 40 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Henan University of Chinese Medicine Coordinator of this site? Confirm its status | Zhengzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.